Tomonori Endo1,2, Daiya Asaka3, Tsuguhisa Nakayama3, Shota Saito3, Hiroki Kodama3, Ryoto Mitsuyoshi3, Shinya Takaishi3, Naoki Sugimoto3, Sachiko Omae3, Hidenori Takagi4, Yuhya Wakasa4, Kenjiro Ozawa4, Makoto Takano4, Fumio Takaiwa4, Hiromi Kojima3, Saburo Saito5. 1. Department of Otorhinolaryngology, Jikei University School of Medicine, Tokyo, Japan, tomonori-endo@jikei.ac.jp. 2. Department of Otorhinolaryngology, Federation of National Public Service Personnel Mutual Aid Associations, Tokyo Kyosai Hospital, Tokyo, Japan, tomonori-endo@jikei.ac.jp. 3. Department of Otorhinolaryngology, Jikei University School of Medicine, Tokyo, Japan. 4. Institute of Agrobiological Sciences, National Agriculture and Food Research Organization, Ibaraki, Japan. 5. Division of Molecular Immunology, Research Center for Medical Science, Jikei University School of Medicine, Tokyo, Japan.
Abstract
BACKGROUND: A rice-based peptide vaccine containing 7 linked human predominant T-cell epitopes (7Crp) derived from Japanese cedar (JC) pollen allergens, Cry j 1 and Cry j 2, was developed. Here, we examined the efficacy and safety of this transgenic rice in JC pollinosis patients. METHODS: Transgenic rice (5, 20, and 80 g) was administered orally. We measured the T-cell proliferative activity against 7Crp, Cry j 1, and Cry j 2; the cytokine expression levels; and specific IgE and IgG4 production levels. In addition, the symptom and medication scores were monitored during the pollen season, and quality of life (QOL) was evaluated. RESULTS: T-cell proliferative activities to Cry j 1, Cry j 2, and 7Crp were significantly depressed in a dose-dependent manner. Oral intake of 80 g transgenic rice for 20 weeks resulted in significant suppression of allergen-specific T-cell proliferation with downregulation of IL-13 and upregulation of IL-10 levels but no changes to specific IgE and IgG4 levels. The QOL symptom scores for allergic rhinitis were not significantly improved. CONCLUSIONS: Allergen-specific T-cell responses were significantly reduced by oral intake of transgenic rice in a dose-dependent manner. However, neither medication score nor QOL symptom scores could be improved during the JC pollen season with oral intake of transgenic rice for 20 weeks.
BACKGROUND: A rice-based peptide vaccine containing 7 linked human predominant T-cell epitopes (7Crp) derived from Japanese cedar (JC) pollen allergens, Cry j 1 and Cry j 2, was developed. Here, we examined the efficacy and safety of this transgenic rice in JC pollinosispatients. METHODS: Transgenic rice (5, 20, and 80 g) was administered orally. We measured the T-cell proliferative activity against 7Crp, Cry j 1, and Cry j 2; the cytokine expression levels; and specific IgE and IgG4 production levels. In addition, the symptom and medication scores were monitored during the pollen season, and quality of life (QOL) was evaluated. RESULTS: T-cell proliferative activities to Cry j 1, Cry j 2, and 7Crp were significantly depressed in a dose-dependent manner. Oral intake of 80 g transgenic rice for 20 weeks resulted in significant suppression of allergen-specific T-cell proliferation with downregulation of IL-13 and upregulation of IL-10 levels but no changes to specific IgE and IgG4 levels. The QOL symptom scores for allergic rhinitis were not significantly improved. CONCLUSIONS: Allergen-specific T-cell responses were significantly reduced by oral intake of transgenic rice in a dose-dependent manner. However, neither medication score nor QOL symptom scores could be improved during the JC pollen season with oral intake of transgenic rice for 20 weeks.
Authors: Wenshu He; Can Baysal; Maria Lobato Gómez; Xin Huang; Derry Alvarez; Changfu Zhu; Victoria Armario-Najera; Aamaya Blanco Perera; Pedro Cerda Bennaser; Andrea Saba-Mayoral; Guillermo Sobrino-Mengual; Ashwin Vargheese; Rita Abranches; Isabel Alexandra Abreu; Shanmugaraj Balamurugan; Ralph Bock; Johannes F Buyel; Nicolau B da Cunha; Henry Daniell; Roland Faller; André Folgado; Iyappan Gowtham; Suvi T Häkkinen; Shashi Kumar; Ramalingam Sathish Kumar; Cristiano Lacorte; George P Lomonossoff; Ines M Luís; Julian K-C Ma; Karen A McDonald; Andre Murad; Somen Nandi; Barry O'Keef; Subramanian Parthiban; Mathew J Paul; Daniel Ponndorf; Elibio Rech; Julio C M Rodrigues; Stephanie Ruf; Stefan Schillberg; Jennifer Schwestka; Priya S Shah; Rahul Singh; Eva Stoger; Richard M Twyman; Inchakalody P Varghese; Giovanni R Vianna; Gina Webster; Ruud H P Wilbers; Paul Christou; Kirsi-Marja Oksman-Caldentey; Teresa Capell Journal: Plant Biotechnol J Date: 2021-07-19 Impact factor: 13.263